NVS
January 31, 2024 - AI Summary
Overvalued by 2.3% based on the discounted cash flow analysis.
Market cap | $202.72 Billion |
---|---|
Enterprise Value | $214.64 Billion |
Dividend Yield | $3.7395 (4.04%) |
Earnings per Share | $7.1 |
Beta | 0.31 |
Outstanding Shares | 2,189,930,497 |
Avg 30 Day Volume | 1,554,341 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 13.65 |
---|---|
PEG | 2.85 |
Price to Sales | 4.63 |
Price to Book Ratio | 4.63 |
Enterprise Value to Revenue | 4.6 |
Enterprise Value to EBIT | 20.87 |
Enterprise Value to Net Income | 14 |
Total Debt to Enterprise | 0.12 |
Debt to Equity | 0.56 |
No data
No data
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...